Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA

Market Focus07-23

On July 23, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $192.03/share, with turnover of $106 million.

On the news front, the FDA formally accepted the company's New Drug Application (NDA) for its core candidate Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer. This acceptance marks a critical regulatory milestone, indicating that the FDA has determined the application materials to be complete and has initiated the substantive review process. Pancreatic cancer, particularly metastatic disease, has long suffered from poor prognosis and limited treatment options, making this development closely watched by the industry.

On the same day, Wedbush raised its price target on Revolution Medicines from $181 to $192.10, maintaining its Outperform rating. According to FactSet, the stock carries an average analyst rating of Buy with a mean price target of $203.85. Notably, the EMA also launched a phased review of Daraxonrasib earlier this month, signaling parallel regulatory progress across major markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115892068?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115892068","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA","media":"Market Focus","content":"<p><p>On July 23, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $192.03/share, with turnover of $106 million.</p><p>On the news front, the FDA formally accepted the company's New Drug Application (NDA) for its core candidate Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer. This acceptance marks a critical regulatory milestone, indicating that the FDA has determined the application materials to be complete and has initiated the substantive review process. Pancreatic cancer, particularly metastatic disease, has long suffered from poor prognosis and limited treatment options, making this development closely watched by the industry.</p><p>On the same day, Wedbush raised its price target on Revolution Medicines from $181 to $192.10, maintaining its Outperform rating. According to FactSet, the stock carries an average analyst rating of Buy with a mean price target of $203.85. Notably, the EMA also launched a phased review of Daraxonrasib earlier this month, signaling parallel regulatory progress across major markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-23 22:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 23, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $192.03/share, with turnover of $106 million.</p><p>On the news front, the FDA formally accepted the company's New Drug Application (NDA) for its core candidate Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer. This acceptance marks a critical regulatory milestone, indicating that the FDA has determined the application materials to be complete and has initiated the substantive review process. Pancreatic cancer, particularly metastatic disease, has long suffered from poor prognosis and limited treatment options, making this development closely watched by the industry.</p><p>On the same day, Wedbush raised its price target on Revolution Medicines from $181 to $192.10, maintaining its Outperform rating. According to FactSet, the stock carries an average analyst rating of Buy with a mean price target of $203.85. Notably, the EMA also launched a phased review of Daraxonrasib earlier this month, signaling parallel regulatory progress across major markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1115892068","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115892068","pubTimestamp":1784816721,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 23, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $192.03/share, with turnover of $106 million.On the news front, the FDA formally accepted the company's New Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"动态警报|Revolution Medicines, Inc.常规交易涨5.06%，核心药物NDA正式受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On July 23, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $192.03/share, with turnover of $106 million.On the news front, the FDA formally accepted the company's New Drug Application (NDA) for its core candidate Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer. This acceptance marks a critical regulatory milestone, indicating that the FDA has determined the application materials to be complete and has initiated the substantive review process. Pancreatic cancer, particularly metastatic disease, has long suffered from poor prognosis and limited treatment options, making this development closely watched by the industry.On the same day, Wedbush raised its price target on Revolution Medicines from $181 to $192.10, maintaining its Outperform rating. According to FactSet, the stock carries an average analyst rating of Buy with a mean price target of $203.85. Notably, the EMA also launched a phased review of Daraxonrasib earlier this month, signaling parallel regulatory progress across major markets.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115892068","isCrawlerRequest":true}